Merit Medical Systems, Inc. (MMSI) Income Statement

The sequence of 7.8% to 9.7% growth rates points to a durable but unspectacular demand profile, consistent with procedure-volume-driven disposables. Because the data does not isolate volume, pricing, or divestiture effects, the durability of this pace cannot be confirmed. Investors should monitor whether the reported growth converges toward the organic rate cited in recent earnings commentary.

The band suggests a product mix weighted toward high-volume disposables rather than premium proprietary devices. The quarter-to-quarter swings likely reflect input cost, mix, and timing effects, though the data alone does not allow their separation. Sustained margins near the high-40s would imply limited room for expansion absent a shift in product mix or manufacturing efficiency.

SG&A absorbed roughly 28% to 31% of revenue across recent quarters, leaving limited evidence of durable overhead efficiency. The higher 2026 operating margins may reflect cost discipline under the efficiency program, though a single quarter's gain does not establish a trend. Investors should watch whether SG&A growth remains below revenue growth over the next several reporting periods.